{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-188977","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.799785+00:00","generated_at":"2026-05-31T15:24:23.087115+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PepGen announces positive Phase 2 data for PGN-EDO51 in DMD: exon skipping 2.15%, dystrophin increase","bullets":["PGN-EDO51 5 mg/kg achieved mean exon skipping of 2.15% in biceps tissue at week 13 (n=3).","Mean muscle-adjusted dystrophin level of 1.49% of normal, +0.70% from baseline; absolute dystrophin 0.61%, +0.26%.","Drug well tolerated; no discontinuations, one mild AE resolved, no kidney or electrolyte issues.","All three patients continue in long-term extension; 10 mg/kg cohort dosing ongoing with results expected in early 2025.","CONNECT2 Phase 2 trial open in UK; US site expected by year-end; design being optimized based on data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-188977","json":"https://secwatch.observer/filing/0001193125-24-188977.json","markdown":"https://secwatch.observer/filing/0001193125-24-188977.md","text":"https://secwatch.observer/filing/0001193125-24-188977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/0001193125-24-188977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/d879173d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:24:23.087115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}